256 related articles for article (PubMed ID: 17046329)
21. Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab.
Kessel C; Königs C; Linde R; Escuriola-Ettinghausen C; Stoll H; Klingebiel T; Dietrich U; Kreuz W
Mol Immunol; 2008 Nov; 46(1):8-15. PubMed ID: 18715645
[TBL] [Abstract][Full Text] [Related]
22. Cellular and humoral systemic and mucosal immune responses stimulated in volunteers by an oral polybacterial immunomodulator "Dentavax".
Petrunov B; Marinova S; Markova R; Nenkov P; Nikolaeva S; Nikolova M; Taskov H; Cvetanov J
Int Immunopharmacol; 2006 Jul; 6(7):1181-93. PubMed ID: 16714223
[TBL] [Abstract][Full Text] [Related]
23. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
Tamimoto Y; Horiuchi T; Tsukamoto H; Otsuka J; Mitoma H; Kimoto Y; Nakashima H; Muta K; Abe Y; Kiyohara C; Ueda A; Nagasawa K; Yoshizawa S; Shimoda T; Harada M
Rheumatology (Oxford); 2008 Jun; 47(6):821-7. PubMed ID: 18397955
[TBL] [Abstract][Full Text] [Related]
24. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.
Lazarus MN; Turner-Stokes T; Chavele KM; Isenberg DA; Ehrenstein MR
Rheumatology (Oxford); 2012 Jul; 51(7):1208-15. PubMed ID: 22337941
[TBL] [Abstract][Full Text] [Related]
25. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Yamaguchi K; Takeda Y; Goto H; Sato N; Koizumi K; Mukai M; Koike T
Br J Haematol; 2007 May; 137(4):349-54. PubMed ID: 17456057
[TBL] [Abstract][Full Text] [Related]
26. Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment.
Muhammad K; Roll P; Einsele H; Dörner T; Tony HP
Arthritis Rheum; 2009 Aug; 60(8):2284-93. PubMed ID: 19644860
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Goldblatt F; Isenberg DA
Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
[TBL] [Abstract][Full Text] [Related]
28. Effects of rituximab on resistant SLE disease including lung involvement.
Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C
Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171
[TBL] [Abstract][Full Text] [Related]
29. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
Levesque MC; St Clair EW
J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
[TBL] [Abstract][Full Text] [Related]
30. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus.
Ng KP; Leandro MJ; Edwards JC; Ehrenstein MR; Cambridge G; Isenberg DA
Ann Rheum Dis; 2006 Jul; 65(7):942-5. PubMed ID: 16269424
[TBL] [Abstract][Full Text] [Related]
31. [Lymphocyte imbalance in autoimmunity].
Manni JA; Guilleron C; Araujo HA
Medicina (B Aires); 1989; 49(2):105-8. PubMed ID: 2640477
[TBL] [Abstract][Full Text] [Related]
32. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.
Nakano S; Morimoto S; Suzuki J; Nozawa K; Amano H; Tokano Y; Takasaki Y
Rheumatology (Oxford); 2008 Feb; 47(2):145-9. PubMed ID: 18160420
[TBL] [Abstract][Full Text] [Related]
33. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
[TBL] [Abstract][Full Text] [Related]
34. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
Podolskaya A; Stadermann M; Pilkington C; Marks SD; Tullus K
Arch Dis Child; 2008 May; 93(5):401-6. PubMed ID: 18039744
[TBL] [Abstract][Full Text] [Related]
35. Drug insight: rituximab in renal disease and transplantation.
Salama AD; Pusey CD
Nat Clin Pract Nephrol; 2006 Apr; 2(4):221-30. PubMed ID: 16932428
[TBL] [Abstract][Full Text] [Related]
36. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
[TBL] [Abstract][Full Text] [Related]
37. Rituximab: a promising therapy in systemic lupus erythematosus.
Thatayatikom A; White AJ
Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
[TBL] [Abstract][Full Text] [Related]
38. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
39. [Cellular and humoral immunity of volunteers consuming diets with various protein levels].
Voĭtko NE; Iatsyshina TA; Vysotskiĭ VG; Konovalova LS
Vopr Pitan; 1985; (3):28-33. PubMed ID: 3875930
[TBL] [Abstract][Full Text] [Related]
40. Effects of simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with immune stimulation markers.
Gonçalves I; Cherfan P; Söderberg I; Nordin Fredrikson G; Jonasson L
Autoimmunity; 2009 Mar; 42(3):203-8. PubMed ID: 19301201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
